Regeneration of Degenerated Brain: A Promising Therapeutic Target
Promoting Synaptic Resilience in Alzheimer's Disease Patients Through Phosphodiesterases Inhibition
A New Generation of Noninvasive NGF-Based Therapies for Alzheimer's Disease
Targeting Oxidative Mechanisms in Alzheimer Disease
Targeting NF-κB Inflammatory and Prosurvival Signalling in Alzheimer's Disease
4 Receptors as Pharmacological Targets for the Treatment of Alzheimer's Disease
Targeting ApoE in Alzheimer's Disease: Liver X Receptor Agonists as Potential Therapeutics
Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer's Disease
RNA Interference of Genes Related to Alzheimer's Disease
Medicinal Plants, Phytochemicals and Alzheimer's Disease
About this book
Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease.
Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.